<DOC>
	<DOCNO>NCT02951728</DOCNO>
	<brief_summary>This Phase I/II Trial Decitabine + R-CHOP Diffuse Large B-Cell Lymphoma</brief_summary>
	<brief_title>Decitabine Plus R-CHOP Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>histologically confirm DLBCL , CD20 positive . must least one site measurable disease , 1.5 cm diameter great . previous treatment . International Prognostic Index &gt; 1 . Able adhere study visit schedule protocol requirement . must laboratory test result within range : Absolute neutrophil count ≥1500/mm3 Platelet count≥75,000/mm3 Serum creatinine≤1.5×upper limit normal ( ULN ) Total bilirubin≤1.5×ULN . Higher level acceptable attribute active hemolysis ineffective erythropoiesis . AST ( SGOT ) ALT ( SGPT ) ≤2×ULN Disease free prior malignancy exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . Women childbearing potential must negative serum pregnancy test prior Decitabine treatment . Women childbearing potential advise avoid become pregnant men advise father child receive treatment Decitabine . The effect Decitabine develop human fetus recommend therapeutic dose unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Age 15 75 year . Ability understand willingness sign write informed consent document . ECOG performance status 02 Patients must serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Patients must condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 28 day baseline . Concurrent use anticancer agent treatment . Known positive HIV . If HbsAg positive , check HBV DNA , DNA positive patient enrol . If HBsAg negative HBcAb positive ( whatever HBsAb status ) , check HBV DNA , DNA positive patient enrol . Known central nervous system involvement lymphoma . Known suspected hypersensitivity Decitabine mannitol . Pregnant lactate woman exclude study risk unborn fetus potential risk nurse infant unknown .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>